Wall Street analysts expect that Merck & Co., Inc. (NYSE:MRK) will report sales of $9.94 billion for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Merck & Co., Inc.’s earnings, with the lowest sales estimate coming in at $9.87 billion and the highest estimate coming in at $10.01 billion. Merck & Co., Inc. reported sales of $9.43 billion during the same quarter last year, which indicates a positive year over year growth rate of 5.4%. The firm is scheduled to issue its next earnings results on Tuesday, May 1st.
According to Zacks, analysts expect that Merck & Co., Inc. will report full-year sales of $9.94 billion for the current fiscal year, with estimates ranging from $41.23 billion to $42.33 billion. For the next fiscal year, analysts anticipate that the business will report sales of $42.05 billion per share, with estimates ranging from $41.36 billion to $43.34 billion. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that cover Merck & Co., Inc..
Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Friday, February 2nd. The company reported $0.98 EPS for the quarter, topping the Zacks’ consensus estimate of $0.94 by $0.04. The firm had revenue of $10.43 billion during the quarter, compared to the consensus estimate of $10.48 billion. Merck & Co., Inc. had a return on equity of 27.73% and a net margin of 6.40%. The firm’s revenue was up 3.1% on a year-over-year basis. During the same period in the prior year, the business earned $0.89 EPS.
Shares of Merck & Co., Inc. (NYSE MRK) traded up $0.30 on Friday, reaching $56.29. The company had a trading volume of 11,731,200 shares, compared to its average volume of 14,648,327. The company has a market cap of $153,358.56, a P/E ratio of 60.53, a P/E/G ratio of 2.30 and a beta of 0.75. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.16 and a current ratio of 1.43. Merck & Co., Inc. has a 52-week low of $53.36 and a 52-week high of $66.80.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 6th. Stockholders of record on Thursday, March 15th will be issued a $0.48 dividend. The ex-dividend date of this dividend is Wednesday, March 14th. This represents a $1.92 annualized dividend and a dividend yield of 3.41%. Merck & Co., Inc.’s dividend payout ratio (DPR) is 206.45%.
Merck & Co., Inc. announced that its Board of Directors has authorized a stock buyback plan on Tuesday, November 28th that permits the company to repurchase $10.00 billion in shares. This repurchase authorization permits the company to reacquire shares of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s leadership believes its stock is undervalued.
In other news, EVP Michael J. Holston sold 12,500 shares of the company’s stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $61.63, for a total transaction of $770,375.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Weir Mirian M. Graddick sold 5,000 shares of the company’s stock in a transaction on Friday, January 12th. The shares were sold at an average price of $58.00, for a total value of $290,000.00. Following the sale, the insider now directly owns 101,484 shares of the company’s stock, valued at $5,886,072. The disclosure for this sale can be found here. In the last 90 days, insiders sold 82,500 shares of company stock valued at $5,026,025. Insiders own 0.25% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Stelac Advisory Services LLC acquired a new position in Merck & Co., Inc. during the second quarter valued at $104,000. Perennial Advisors LLC raised its position in Merck & Co., Inc. by 10.7% during the second quarter. Perennial Advisors LLC now owns 1,626 shares of the company’s stock valued at $104,000 after buying an additional 157 shares during the period. Solaris Asset Management LLC raised its position in Merck & Co., Inc. by 6.3% during the second quarter. Solaris Asset Management LLC now owns 1,940 shares of the company’s stock valued at $124,000 after buying an additional 115 shares during the period. Santori & Peters Inc. acquired a new position in Merck & Co., Inc. during the fourth quarter valued at $110,000. Finally, Stevens First Principles Investment Advisors raised its position in Merck & Co., Inc. by 79.3% during the fourth quarter. Stevens First Principles Investment Advisors now owns 2,080 shares of the company’s stock valued at $117,000 after buying an additional 920 shares during the period. 72.65% of the stock is owned by institutional investors and hedge funds.
About Merck & Co., Inc.
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.